InsiderTrades

Form 4 for ENTA ENANTA PHARMACEUTICALS INC

Accepted 2022-04-05 00:00:00 ET · period of report 2022-04-01 · accession 0001062993-22-009836 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-04-05 2022-04-01+ ENTA Adda Nathalie SVP, Chief Medical Off M - OptEx $40.63 +83.3K 67.8K New +$3.39M
DM 2022-04-05 2022-04-01+ ENTA Adda Nathalie SVP, Chief Medical Off S - Sale+OE $71.60 -83.3K 35.0K -70% -$5.97M
DM 2022-04-05 2022-04-01+ ENTA Adda Nathalie SVP, Chief Medical Off M - OptEx $0.00 -83.3K 13.1K -86% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-04-01 M A 16,000 $31.42 50,982 D — —
2 Common Common Stock 2022-04-04 S D 2,500 $70.56 65,267 D — — (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
3 Common Common Stock 2022-04-01 M A 2,895 $48.52 85,541 D — —
4 Common Common Stock 2022-04-01 M A 31,664 $30.00 82,646 D — —
5 Common Common Stock 2022-04-04 M A 6,285 $48.52 41,267 D — —
6 Common Common Stock 2022-04-04 M A 9,625 $43.57 50,892 D — —
7 Common Common Stock 2022-04-04 M A 16,875 $63.35 67,767 D — —
8 Common Common Stock 2022-04-04 S D 9,009 $73.42 34,982 D — — (F7) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
9 Common Common Stock 2022-04-04 S D 3,200 $72.65 43,991 D — — (F6) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
10 Common Common Stock 2022-04-04 S D 18,076 $71.71 47,191 D — — (F5) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
11 Common Common Stock 2022-04-01 S D 8,299 $70.75 77,242 D — — (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
12 Common Common Stock 2022-04-01 S D 42,260 $71.32 34,982 D — — (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
13 Derivative Stock Option (Right to Buy) 2022-04-01 M D 16,000 $0.00 0 D $31.42 · — to 2025-11-20 16,000 Common Stock (F8) 100% of the shares subject to the option are fully vested and exercisable.
14 Derivative Stock Option (Right to Buy) 2022-04-01 M D 31,664 $0.00 0 D $30.00 · — to 2026-11-18 31,664 Common Stock (F8) 100% of the shares subject to the option are fully vested and exercisable.
15 Derivative Stock Option (Right to Buy) 2022-04-01 M D 2,895 $0.00 6,285 D $48.52 · — to 2027-11-17 2,895 Common Stock (F8) 100% of the shares subject to the option are fully vested and exercisable.
16 Derivative Stock Option (Right to Buy) 2022-04-04 M D 6,285 $0.00 0 D $48.52 · — to 2027-11-17 6,285 Common Stock (F8) 100% of the shares subject to the option are fully vested and exercisable.
17 Derivative Stock Option (Right to Buy) 2022-04-04 M D 9,625 $0.00 21,175 D $43.57 · — to 2030-11-20 9,625 Common Stock (F9) The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
18 Derivative Stock Option (Right to Buy) 2022-04-04 M D 16,875 $0.00 13,125 D $63.35 · — to 2029-11-18 16,875 Common Stock (F10) The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).